Reactivating HIV-1 from Latency: Insights and Approaches for Targeted Therapy

Feb 26, 2025

10 likes | 79 Views

Explore strategies and mechanisms to reactivate latent HIV-1 for potential therapeutic interventions. Learn about current research and promising approaches in HIV-1 latency reversal. Stay informed on the latest developments in HIV treatment.

Share Presentation

Embed Code

vila

Download Presentation

Reactivating HIV-1 from Latency: Insights and Approaches for Targeted Therapy

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

Table 1to reactivate HIV-1 from latency

Table 1

Table 1. All figures quoted are for multivariate analyses of the predictive effect of transthoracic echocardiography.

189 views • 2 slides

Table 1 :

LANDSAT ETM+ IMAGE: Date July 1999. Fig. 1. Fig. 2. Fig. 4. Fig. 3. COMPARATIVE ANALYSIS OF DIFFERENT RESERVOIR SURVEYING METHODOLOGIES FOR THE OPTIMUM VOLUMETRIC COMPUTATION OF FLUVIAL SEDIMENT DEPOSITS Demetris Zarris 1 , Evdoxia Lykoudi 2

174 views • 1 slides

Table 1

ADRLH-66 : Complementary Therapy Use in HIV+ people: An Online Community Survey Nelson Vergel , Program for Wellness Restoration, Houston, Texas powertx@aol.com, powerusa.org. Table 1. Introduction. Figure 3. Results. Conclusions.

132 views • 1 slides

A new molecular mechanism for HIV-1 latency

Laboratory of Experimental Virology. A new molecular mechanism for HIV-1 latency HIV latency in primary T cells: natural activation/purging by DCs Ben Berkhout Academic Medical Center University of Amsterdam. SOLiD RNA sequences from HIV-1 infected cells.

338 views • 16 slides

Table 1-1, p.3

Table 1-1, p.3. N 2. O 2. animal respiration decaying organic matter oxidation. soil/plants plankton. decaying plants & animals. plant photosynthesis. CO 2. decaying plants volcanic eruptions animal exhalation burning of fossil fuels deforestation. plant photosynthesis.

212 views • 9 slides

Table 1

Filter 1: BU Level 1 State1 State2 State3 State4 State5 State6 State7 State8 State9 State10. Table 1. Table 2. Table 3. Table 4. Table 5. Table 6. Filter 1: BU Level 2 City A City B City C City D City E City F City G City H City I City J. Table 7. Table 8. Table 9.

211 views • 1 slides

Supplementary Table 1

Supplementary Table 1. A.

172 views • 9 slides

Table 1 to reactivate HIV-1 from latency

Table 1 to reactivate HIV-1 from latency.

82 views • 1 slides

Supplementary table 1.

Supplementary table 1. Strains used in this study. Strain. Genotype. Reference. ho∆ MAT α ::URA3::HOcs hml∆::ADE1 hmr∆::ADE1 ade1-100 leu2-3,112 lys5 trp1::hisG ura3-52 ade3::GAL::HO. SLY19. S. Lee et al. 2003.

105 views • 1 slides

TABLE 1

TABLE 1. GOVERNOR'S BUDGET PROPOSAL. Projected State Deficit. $25.4 Billion. Rebuild State Reserve. $1.0 Billion. Total Resolutions Needed. $26.4 Billion. Includes $1.4 Billion in. Budget Reduction Initiatives:. reductions to Higher Ed:. e.g., Budget Cuts, Borrowing from.

250 views • 11 slides

Supplementary Table 1

Supplementary Table 1. Primers used for qRT-PCR. Supplementary Table 2.

160 views • 3 slides

Supplemental Table 1

Supplemental Table 1.

80 views • 1 slides

Additional File 1: Table 1

Additional File 1: Table 1.

95 views • 1 slides

Table 1

Prediction of Absconding from a Halfway House Damon Mitchell, Central Connecticut State University Jake Villeneuve , The Connection, Inc Raymond Chip Tafrate, Central Connecticut State University. Results Descriptive Data 13% of clients (n = 18) absconded from the halfway house.

209 views • 1 slides

Table 13-1

Table 13-1. Figure 13-1 - Overview. Figure 13-1a. Figure 13-1b. Figure 13-2. Figure 13-3 - Overview. Figure 13-3a. Figure 13-3b. Figure 13-3c. Figure 13-4a. Figure 13-4b. Figure 13-5a. Figure 13-5b. Figure 13-6 - Overview. Figure 13-6a. Figure 13-6b. Figure 13-6c. Figure 13-6d.

551 views • 41 slides

Table 1

Table 1. 116 kDa. 45 kDa. 35 kDa. 25 kDa. 18,8 kDa. 14,4 kDa. A. B. Antigenic targets RA SM. Antigenic targets wrist RA SM. Finger. Wrist. Knee. Hip. Healthy control sera. RA sera. RA serum. RA serum. RA serum. RA serum. Healthy serum. Healthy serum. Healthy serum.

257 views • 9 slides

Table 1

Table 1. Numbers of people using direct payments in England. 30/9/2001. 30/9/2002. 30/9/2003. 30/9/2004. 3/3/2005. Total number of Recipients. 5,423. 7,882. 12,585. 19,567. 24,744. Older people (65+). 537. 1,032. 1,899. 4,365. 5,493. People with learning disabilities. 353.

129 views • 1 slides

Table 1

Table 1 Parameters of length ratio (length to initial length) variation model for beans during drying (L/L 0 = A + B MR) L:D ratio A B R 2 1:1 0.6731 0.3757 0.80

142 views • 1 slides

Table 1

Table 1.

100 views • 1 slides

Table 1

Table 1. Among 19 European Nations,Predicted Awards for Pain and Suffering In the Median Nation By Type of Injury (1000s of Euros). Table 2 National Award Proportion For Each Injury as a % of Highest Predicted for Each Nation. Table 3 European “Vertical Equity”.

310 views • 21 slides

Table 1

Table 1. Judge DP (2008) E713K in desmoglein-2 and arrhythmogenic right ventricular dysplasia/cardiomyopathy Nat Clin Pract Cardiovasc Med doi:10.1038/ncpcardio1351.

99 views • 1 slides

Supplementary Table 1

Supplementary Table 1. Clinical Characteristics of human volunteers. Group I : Normal. Group II : CRS. Supplementary Table 2. Antibodies used for immunofluoresent microscopy. Supplementary Table 3. Antibodies used for mouse flow cytometry.

73 views • 5 slides

More Related